# Medeor Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/medeor-therapeutics

- Industry: Biotechnology
- Headquarters: South San Francisco, US
- Website: www.medeortx.com
- Total disclosed funding: $57M
- Latest round: Series B (Nov 27, 2017)
- Investors on record: 4

## About

Medeor Therapeutics focuses on pioneering cellular immunotherapy solutions to enhance outcomes for kidney transplant patients, utilizing innovative techniques to minimize reliance on immunosuppressants.Founded in 2012 and headquartered in South San Francisco, US, Medeor Therapeutics specializes in cellular immunotherapy to improve kidney transplant success. The company was established through a combination of research from Stanford University and innovative approaches in the transplant field. Currently, Giovanni Ferrara serves as CEO. Medeor Therapeutics has successfully raised a total of USD 57.00 mn, including a recent GRANT of USD 18.80 mn led by the California Institute for Regenerative Medicine, highlighting its focus on advancing clinical trials.Medeor Therapeutics specializes in innovative cellular immunotherapy aimed at improving outcomes for kidney transplant recipients. The company’s core offering is a breakthrough therapy that utilizes mixed chimerism, allowing for the co-existence of donor and recipient immune cells, thereby promoting prolonged organ survival without the continuous need for immunosuppressant drugs. This technology platform, which originated from research at Stanford University over two decades ago, has advanced through a pivotal Phase 3 clinical trial targeting HLA-matched living donor kidney-transplant recipients. The end use case addresses significant challenges in the transplant community, including the rejection rates that range from 30-50% within ten years post-transplant. Medeor's services primarily cater to transplant patients and healthcare providers in North America and Europe, focusing on improving the quality of life for both recipients and donors through enhanced organ tolerance.Information regarding Medeor Therapeutics' revenue structure is not publicly disclosed. However, the company operates within a clinical trial framework that likely involves partnerships with healthcare institutions and hospitals to facilitate its Phase 3 studies and potential future product launches. Revenue generation is anticipated to be derived from the successful commercialization of its flagship immunotherapy, which is expected to involve direct sales to healthcare facilities and possibly collaborations with larger pharmaceutical companies for distribution. As the company moves towards filing for biologics license approval (BLA), its revenue model may evolve to include subscription or partnership arrangements with healthcare systems for the provision of its therapies. The pricing structure for treatments is not specified, but given the nature of advanced cellular therapies, it is expected to reflect the high value placed on the improved outcomes and quality of life for transplant patients.Medeor Therapeutics plans to enhance its product offerings with new therapies targeting additional transplant scenarios, although specific release dates have yet to be disclosed. The company aims to expand its services into new markets across Europe and Asia by 2025, enhancing the reach of its innovative immunotherapy solutions. Recent funding of USD 18.80 mn will support these initiatives, enabling further clinical research and potential partnerships in these regions. Additionally, the company is exploring potential collaborations with larger pharmaceutical firms to strengthen its market presence and expedite product availability.

## Funding rounds

- Series B, Nov 27, 2017, $57M — Sofinnova Investments, Vivo Capital, RA Capital Management, 6 Dimensions Capital

## Investors

- Sofinnova Investments (https://capitalatlas.ai/funds/sofinnova-investments) — Series B
- Vivo Capital (https://capitalatlas.ai/funds/vivo-capital) — Series B
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series B
- 6 Dimensions Capital (https://capitalatlas.ai/funds/6-dimensions-capital) — Series B